Technical Analysis for STTK - Shattuck Labs, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Up |
| Historical STTK trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| 1,2,3 Retracement Bearish | Bearish Swing Setup | 8.93% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 8.93% | |
| MACD Bullish Signal Line Cross | Bullish | 8.93% | |
| Spinning Top | Other | 8.93% | |
| Outside Day | Range Expansion | 8.93% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Up 10% | about 3 hours ago |
| 1.5x Volume Pace | about 7 hours ago |
| 60 Minute Opening Range Breakout | about 7 hours ago |
| Rose Above Previous Day's High | about 7 hours ago |
| Rose Above 10 DMA | about 7 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Sector: Other
Industry: Other
Keywords: Biotechnology Cancer Life Sciences Pharmaceutical Industry Solid Tumors Treatment Of Cancer Lymphoma Autoimmune Disease Clinical Research Clinical Trial Ovarian Cancer Takeda Pharmaceutical Company Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer
Classification
Sector: Other
Industry: Other
Keywords: Biotechnology Cancer Life Sciences Pharmaceutical Industry Solid Tumors Treatment Of Cancer Lymphoma Autoimmune Disease Clinical Research Clinical Trial Ovarian Cancer Takeda Pharmaceutical Company Advanced Solid Tumors Clinical Pharmacology Treatment Of Ovarian Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 60.5162 |
| 52 Week Low | 17.51 |
| Average Volume | 112,368 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 38.71 |
| 20-Day Moving Average | 31.42 |
| 10-Day Moving Average | 28.70 |
| Average True Range | 3.20 |
| ADX | 34.84 |
| +DI | 16.98 |
| -DI | 22.66 |
| Chandelier Exit (Long, 3 ATRs ) | 31.33 |
| Chandelier Exit (Short, 3 ATRs ) | 35.17 |
| Upper Bollinger Band | 38.18 |
| Lower Bollinger Band | 24.65 |
| Percent B (%b) | 0.45 |
| BandWidth | 43.04 |
| MACD Line | -2.90 |
| MACD Signal Line | -3.17 |
| MACD Histogram | 0.2769 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 36.39 | ||||
| Resistance 3 (R3) | 35.91 | 33.54 | 35.45 | ||
| Resistance 2 (R2) | 33.54 | 32.11 | 33.79 | 35.14 | |
| Resistance 1 (R1) | 32.15 | 31.22 | 32.85 | 32.63 | 34.82 |
| Pivot Point | 29.78 | 29.78 | 30.13 | 30.03 | 29.78 |
| Support 1 (S1) | 28.39 | 28.35 | 29.09 | 28.87 | 26.68 |
| Support 2 (S2) | 26.02 | 27.46 | 26.27 | 26.36 | |
| Support 3 (S3) | 24.63 | 26.02 | 26.05 | ||
| Support 4 (S4) | 25.11 |
